SecBot SecBot
8-K ·Filed Jun 22, 2026

AWHL

Aspira Women's Health Inc.
BEARISH
Impact 5/10
Horizonweeks Processed3mo ago SEC0000926617-26-000047
8-K context-dependent: Items 5.02
Actionable Insight ▼ Bearish

The sudden CEO departure at a small-cap diagnostics company creates leadership uncertainty. Monitor the search for a permanent CEO and any separation agreement terms in the upcoming 8-K amendment. The appointment of the Chairman as interim CEO provides some stability, but the lack of a finalized separation agreement adds risk.

DirectionBearish
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
AWHL ▼ -36.96% at T+60d
SHORT call ✓ call won +36.96% · α vs SPY +39.17% · entry $0.4600 → $0.2900
Entry = T+0 close
Jun 22, 2026
via day close
T+1d
-10.87%
call +10.87% · α +9.42%
$0.4100
settled 4mo ago
T+5d
-2.17%
call +2.17% · α +1.72%
$0.4500
settled 4mo ago
T+20d
-17.39%
call +17.39% · α +17.08%
$0.3800
settled 3mo ago
T+60d
-36.96%
call +36.96% · α +39.17%
$0.2900
settled 6w ago

Price Chart

Loading chart...

Executive Summary

CEO Michael Buhle departed Aspira Women's Health on June 17, 2026, with Chairman John Fraser appointed as Interim CEO while a search for a permanent replacement is conducted. The filing states the departure was not due to any disagreement with the company, and separation terms are not yet finalized.

Key Facts

  • CEO Michael Buhle ceased serving as CEO on June 17, 2026
  • Chairman John Fraser appointed Interim CEO and Principal Executive Officer effective June 17, 2026
  • A search for internal and external candidates is underway
  • Departure was not due to any disagreement with the company per the filing
  • Separation agreement terms are not yet finalized; an amendment will be filed within 4 business days

Financial Impact

No financial figures disclosed in the filing

Risk Factors

  • Leadership vacuum during CEO search could disrupt operations and strategy
  • Uncertainty around separation terms with former CEO may lead to additional costs or litigation
  • Small-cap OTC-traded company faces execution risk during leadership transition

Market Snapshot

Exchange
OTC
Sector
In Vitro & In Vivo Diagnostic Substances
Analyst Consensus
80% bullish (5 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000926617-26-000047
Document: 0000926617-26-000047-index-headers.html0000926617-26-000047
Document: 0000926617-26-000047-index.html0000926617-26-000047
Document: 0000926617-26-000047.txt0000926617-26-000047
6 reports for AWHL
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for AWHL — sortable, filterable
TypeNow
Jun 22, 2026
18w ago
8-K
BEARISH ★ 5/10
$0.4600 $0.2900▲ +36.96%▲ +39.17%$0.1387 (+69.85%)
Jun 9, 2026
20w ago
8-K
BEARISH ★ 6/10
$0.4300 $0.2786▲ +35.21%▲ +39.29%$0.1387 (+67.74%)
May 29, 2026
21w ago
Insider Cluster
BULLISH ★ 5/10
$0.5400 $0.2700▼ −50.00%▼ −51.23%$0.1387 (−74.31%)
May 26, 2026
22w ago
8-K
NEUTRAL ★ 4/10
$0.4600 $0.3100▼ −32.61%▼ −35.33%$0.1387 (−69.85%)
Apr 30, 2026
25w ago
8-K
NEUTRAL ★ 3/10
$0.3900 $0.3509▼ −10.03%▼ −13.09%$0.1387 (−64.44%)
Apr 28, 2026
25w ago
DEFA14A
NEUTRAL ★ 3/10
$0.4000 $0.4000· 0.00%▼ −4.11%$0.1387 (−65.33%)
Showing 6 of 6

US Market Status

Market Open — Closes in 2h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026